Huang Elijah Ejun, Zhang Ning, Ganio Edward A, Shen Huaishuang, Li Xueping, Ueno Masaya, Utsunomiya Takeshi, Maruyama Masahiro, Gao Qi, Su Ni, Yao Zhenyu, Yang Fan, Gaudillière Brice, Goodman Stuart B
Department of Orthopaedic Surgery, Stanford University, Stanford, CA, USA.
Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University, Stanford, CA, USA.
J Orthop Translat. 2022 Aug 4;36:64-74. doi: 10.1016/j.jot.2022.05.010. eCollection 2022 Sep.
A critical size bone defect is a clinical scenario in which bone is lost or excised due to trauma, infection, tumor, or other causes, and cannot completely heal spontaneously. The most common treatment for this condition is autologous bone grafting to the defect site. However, autologous bone graft is often insufficient in quantity or quality for transplantation to these large defects. Recently, tissue engineering methods using mesenchymal stem cells (MSCs) have been proposed as an alternative treatment. However, the underlying biological principles and optimal techniques for tissue regeneration of bone using stem cell therapy have not been completely elucidated.
In this study, we compare the early cellular dynamics of healing between bone graft transplantation and MSC therapy in a murine chronic femoral critical-size bone defect. We employ high-dimensional mass cytometry to provide a comprehensive view of the differences in cell composition, stem cell functionality, and immunomodulatory activity between these two treatment methods one week after transplantation.
We reveal distinct cell compositions among tissues from bone defect sites compared with original bone graft, show active recruitment of MSCs to the bone defect sites, and demonstrate the phenotypic diversity of macrophages and T cells in each group that may affect the clinical outcome.
Our results provide critical data and future directions on the use of MSCs for treating critical size defects to regenerate bone. This study showed systematic comparisons of the cellular and immunomodulatory profiles among different interventions to improve the healing of the critical-size bone defect. The results provided potential strategies for designing robust therapeutic interventions for the unmet clinical need of treating critical-size bone defects.
临界尺寸骨缺损是一种临床情况,即由于创伤、感染、肿瘤或其他原因导致骨组织丢失或切除,且无法自发完全愈合。针对这种情况最常见的治疗方法是将自体骨移植到缺损部位。然而,自体骨移植的数量或质量往往不足以移植到这些大的缺损处。最近,有人提出使用间充质干细胞(MSCs)的组织工程方法作为一种替代治疗方法。然而,使用干细胞疗法进行骨组织再生的潜在生物学原理和最佳技术尚未完全阐明。
在本研究中,我们比较了小鼠慢性股骨临界尺寸骨缺损中骨移植与间充质干细胞治疗后早期愈合的细胞动力学。我们采用高维质谱流式细胞术,以全面了解移植一周后这两种治疗方法在细胞组成、干细胞功能和免疫调节活性方面的差异。
我们揭示了与原始骨移植相比,骨缺损部位组织中不同的细胞组成,显示间充质干细胞被积极募集到骨缺损部位,并证明每组中巨噬细胞和T细胞的表型多样性可能影响临床结果。
我们的结果为使用间充质干细胞治疗临界尺寸骨缺损以再生骨提供了关键数据和未来方向。本研究系统比较了不同干预措施之间的细胞和免疫调节特征,以促进临界尺寸骨缺损的愈合。研究结果为针对治疗临界尺寸骨缺损这一未满足的临床需求设计有效的治疗干预措施提供了潜在策略。